

WELL LIFE COMPOUNDING PHARMACY

CANINE GENERALIZED DEMODICOSIS

The following clinical study found that daily use of ivermectin, at a dosage of 0.6 mg/kg, PO, was found to be effective in the treatment of generalized demodicosis in dogs –“Ivermectin for treatment of generalized demodicosis in dogs” (J Am Vet Med Assoc. 1995 Nov 15;207(10).1308-10).

OBJECTIVE: To evaluate the efficacy of daily administration of ivermectin in the treatment of dogs with amitraz-resistant generalized demodicosis.

DESIGN: Prospective, clinical trial.

ANIMALS: Twelve privately owned dogs with juvenile-onset of adult-onset generalized demodicosis that had failed to respond to biweekly or weekly applications of 0.025% amitraz solution.

PROCEDURE: All dogs were treated with undiluted ivermectin at a dosage of 0.6 mg/kg of body weight, PO, every 24 hours. There was no other parasitocidal agent given topically or systemically. A physical examination and multiple skin scrapings were performed every 2 to 4 weeks while dogs were receiving ivermectin. Skin scrapings were performed at approximately the same sites at every examination. After no mites were seen, treatment was continued for at least 2 more weeks and then stopped. Dogs were reexamined, and skin scrapings were repeated if any skin lesions developed. For dogs that remained clinically normal, follow-up information was obtained by telephone. Dogs that were free of clinical signs of demodicosis 12 months after ivermectin administration was discontinued were considered cured.

RESULTS: Ten of 12 dogs were cured. Median duration of treatment for these dogs was 10 weeks (range, 6 weeks to 5 months). Two dogs were failures, relapsing 10 months and 11.5 months after treatment was stopped. One of these dogs was successfully treated with a second course of ivermectin. Mild ivermectin toxicosis developed in one dog after 6 weeks of treatment: side effect resolved shortly after the treatment was stopped.

CLINICAL IMPLICATIONS: Daily use of ivermectin, at a dosage of 0.6mg/kg PO, was found to be effective in the treatment of generalized demodicosis in dogs. PMID: 7591924

WELL LIFE COMPOUNDING PHARMACY

CANINE GENERALIZED DEMODICOSIS

This study found oral ivermectin to be as effective as Advocate- "Treatment of canine-generalized demodicosis: a blind, randomized clinical trial comparing the efficacy of Advocate (Bayer Animal Health) with ivermectin" (Vet Dermatol. 2009 Oct;20(5-6):447-55).

ABSTRACT: "Advocate (moxidectin 2.5% + imidacloprid 10%) is a multiparasiticide agent authorized for treating canine demodicosis in many countries. This blind, randomized clinical trial assessed the efficacy of Advocate at varying treatment intervals and compared it with that of oral ivermectin. Fifty dogs with generalized demodicosis were randomly assigned to one of four treatment groups: oral ivermectin (500mcg/kg once daily), Advocate applied at the authorized dose monthly (ADV1), every 2 weeks (ADV2), or weekly (ADV4). Each dog was evaluated every 4 weeks for 4 months or until negative scrapings at all sites resulted on two successive evaluations (parasitological cure). Miticidal efficacy was determined through deep skin scrapings taken from the same three sites on each occasion. Total numbers of live and dead adult mites, juveniles and eggs were determined. Thirty-five dogs completed the 4 month trial. Parasiticide efficacy was assessed using several parameters including reduction in live adult mite counts. Ancova analysis for this parameter confirmed that there were differences in efficacy among the treatment groups ($P < 0.002$). Tukey-Kramer all pairwise multiple comparison tests revealed that ADV4 was more effective than ADV1 ($P = 0.016$). Ivermectin was more effective than ADV1 ($P = 0.003$). Both ivermectin and ADV4 showed clinically substantial reductions in adult mite counts (89% for ADV4 and 98% for ivermectin). In conclusion, the efficacy of Advocate increased with the rate of application and weekly application may represent a new approach to the treatment of canine generalized demodicosis." PMID: 20178483

We have the ability to compound ivermectin as a capsule.

Example of how you might prescribe:

